Literature DB >> 14768012

Hepatitis C. Development of new drugs and clinical trials: promises and pitfalls. Summary of an AASLD hepatitis single topic conference, Chicago, IL, February 27-March 1, 2003.

Jean-Michel Pawlotsky1, John G McHutchison.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 14768012     DOI： 10.1002/hep.20065

Source DB:  PubMed          Journal:  Hepatology        ISSN： 0270-9139            Impact factor:   17.425


× No keyword cloud information.
  11 in total

Review 1.  Mortality from cirrhosis: lack of progress over the last 35 years.

Authors:  C Gluud
Journal:  Gut       Date:  2005-11       Impact factor: 23.059

2.  Dynamic range of hepatitis C virus RNA quantification with the Cobas Ampliprep-Cobas Amplicor HCV Monitor v2.0 assay.

Authors:  Karine Gourlain; Alexandre Soulier; Bertrand Pellegrin; Magali Bouvier-Alias; Christophe Hézode; Françoise Darthuy; Jocelyne Rémiré; Jean-Michel Pawlotsky
Journal:  J Clin Microbiol       Date:  2005-04       Impact factor: 5.948

3.  Betulinic acid exerts anti-hepatitis C virus activity via the suppression of NF-κB- and MAPK-ERK1/2-mediated COX-2 expression.

Authors:  Chun-Kuang Lin; Chin-Kai Tseng; Kai-Hsun Chen; Shih-Hsiung Wu; Chih-Chuang Liaw; Jin-Ching Lee
Journal:  Br J Pharmacol       Date:  2015-08-03       Impact factor: 8.739

4.  Discovery of naturally occurring aurones that are potent allosteric inhibitors of hepatitis C virus RNA-dependent RNA polymerase.

Authors:  Romain Haudecoeur; Abdelhakim Ahmed-Belkacem; Wei Yi; Antoine Fortuné; Rozenn Brillet; Catherine Belle; Edwige Nicolle; Coralie Pallier; Jean-Michel Pawlotsky; Ahcène Boumendjel
Journal:  J Med Chem       Date:  2011-07-06       Impact factor: 7.446

Review 5.  Children with hepatitis C.

Authors:  Girish Subba Rao; Jean Pappas Molleston
Journal:  Curr Gastroenterol Rep       Date:  2005-02

6.  Analytical variables influencing the HCV RNA determination by TaqMan real-time PCR in routine clinical laboratory practice.

Authors:  Abida Raza; Zameer Ali; Javaid Irfan; Shahnaz Murtaza; Samina Shakeel
Journal:  Mol Biol Rep       Date:  2012-02-12       Impact factor: 2.316

7.  Development of an intergenotypic hepatitis C virus (HCV) cell culture method to assess antiviral susceptibilities and resistance development of HCV NS3 protease genes from HCV genotypes 1 to 6.

Authors:  Ingrid Imhof; Peter Simmonds
Journal:  J Virol       Date:  2010-02-17       Impact factor: 5.103

Review 8.  Treatment of hepatitis C virus infection.

Authors:  Kilian Weigand; Wolfgang Stremmel; Jens Encke
Journal:  World J Gastroenterol       Date:  2007-04-07       Impact factor: 5.742

9.  Occurrence of genetic modifications in core, 5'UTR and NS5b of HCV associated with viral response to treatment.

Authors:  Sobia Kanwal; Tariq Mahmood
Journal:  Virol J       Date:  2014-09-30       Impact factor: 4.099

10.  Evaluation of persistence of resistant variants with ultra-deep pyrosequencing in chronic hepatitis C patients treated with telaprevir.

Authors:  Xiomara V Thomas; Joep de Bruijne; James C Sullivan; Tara L Kieffer; Cynthia K Y Ho; Sjoerd P Rebers; Michel de Vries; Hendrik W Reesink; Christine J Weegink; Richard Molenkamp; Janke Schinkel
Journal:  PLoS One       Date:  2012-07-27       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.